Y-27632 dihydrochloride: Selective ROCK Inhibitor for Rho/ROCK Pathway Research

Executive Summary: Y-27632 dihydrochloride is a highly selective small-molecule inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with IC50 values of ~140 nM and Ki of 300 nM, respectively (APExBIO). This compound exhibits over 200-fold selectivity versus other kinases, enabling precise disruption of Rho-mediated actin cytoskeletal dynamics in cellular models. Y-27632 is cell-permeable, water-soluble, and suitable for in vitro and in vivo use. It supports stem cell survival, inhibits tumor invasion, and is a critical tool for investigating the Rho/ROCK signaling pathway in cancer and cell biology. Experimental use protocols and storage conditions are well-characterized, facilitating reproducible research outcomes (Nick et al., 2024).

Biological Rationale

Rho-associated protein kinases (ROCK1/2) are central regulators of actin cytoskeleton dynamics, cell contractility, cell cycle progression, and motility. Aberrant ROCK signaling is implicated in tumor metastasis, fibrosis, and vascular diseases (Advanced Insights Article). As a selective ROCK inhibitor, Y-27632 dihydrochloride enables researchers to dissect the role of Rho/ROCK pathways in cellular mechanics and signal transduction. Unlike non-selective kinase inhibitors, Y-27632 allows targeted inhibition, minimizing confounding off-target effects in cellular systems. This article extends previous reviews (Strategic ROCK Inhibition) by detailing quantitative benchmarks and practical workflows for APExBIO's A3008 reagent.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride functions as a competitive inhibitor, targeting the ATP-binding catalytic domains of ROCK1 and ROCK2. It blocks kinase activity with a reported IC50 of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2 (APExBIO). The compound demonstrates greater than 200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK, and PAK. Inhibition of ROCK disrupts phosphorylation of downstream targets, leading to dissolution of actin stress fibers, reduced focal adhesion formation, and modulation of cell cycle transitions (G1 to S phase). In stem cell cultures, Y-27632 prevents apoptosis by interfering with stress fiber-mediated contractility. In cancer models, it limits tumor cell invasion and metastasis by altering cytoskeletal organization.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC50 of ~140 nM and ROCK2 with a Ki of 300 nM under standard kinase assay conditions (APExBIO; product data).
• Demonstrates >200-fold selectivity against closely related kinases, including PKC, MLCK, and PAK (product documentation).
• In vitro, Y-27632 reduces prostatic smooth muscle cell proliferation in a concentration-dependent manner (10–50 μM; 37°C, 5% CO₂) (Nick et al., 2024).
• In vivo, Y-27632 decreases tumor invasion and metastatic spread in mouse xenograft models (dosing: 10 mg/kg, IP, daily for 21 days) (Precision ROCK Inhibition).
• Stock solutions are stable for several months at ≤–20°C; aqueous solubility reaches up to 52.9 mg/mL at 37°C (APExBIO).
• Y-27632 enhances survival of dissociated human embryonic stem cells at 10 μM, improving colony formation efficiency by up to 25% versus controls (culture: mTeSR1, 5% CO₂, 24 h) (Scenario-Driven Solutions).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely applied in the following contexts:

• Cell-permeable ROCK inhibitor for cytoskeletal and contractility studies.
• Enhancement of stem cell viability during passaging and cryopreservation.
• Suppression of tumor invasion, metastasis, and pathological tissue remodeling.
• Investigation of cell cycle transitions and cytokinesis in mammalian cells.

This article extends prior analyses (Strategic Precision in Rho/ROCK Pathway Modulation) by providing updated solubility and storage data, and offering a detailed side-by-side comparison of in vitro and in vivo efficacy benchmarks.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit all serine/threonine kinases—selectivity is limited to ROCK1/2.
• Long-term storage of aqueous solutions at room temperature leads to degradation and loss of activity.
• Not effective in models where cytoskeletal changes are driven by Rho-independent pathways.
• High concentrations (>100 μM) may cause off-target effects in sensitive primary cell cultures.
• Does not substitute for genetic knockout in elucidating non-catalytic ROCK functions.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid by APExBIO (SKU A3008). For typical use, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water, using gentle warming (37°C) or sonication to enhance solubility. Prepare fresh aliquots and store below –20°C for up to several months. Avoid repeated freeze–thaw cycles. In cell culture, start with 10 μM final concentration for cytoskeletal or viability assays; titrate as required. For in vivo experiments, dosing regimens commonly range from 1–30 mg/kg, administered intraperitoneally. Always confirm batch-specific purity and activity by referencing the manufacturer's datasheet (A3008 kit).

Conclusion & Outlook

Y-27632 dihydrochloride remains the gold standard for selective chemical inhibition of ROCK1/2 in cell and animal models. Its robust selectivity, reproducible performance, and broad adoption make it indispensable for dissecting Rho/ROCK signaling mechanisms. Future research may explore combinatorial approaches with genetic tools or next-generation kinase inhibitors. For additional mechanistic and translational perspectives, consult the Advanced Insights article, which this review extends by providing quantitative workflows and updated benchmarks. For product specifications and ordering, see the official APExBIO Y-27632 dihydrochloride page.